Company: BLLN
Filing Date: 2025-10-17
Form Type: S-1/A
Source: 0001193125-25-242632
Chunk: 301

Company: BillionToOne, Inc.
Filing Date: 2025-10-17
Form: S-1/A
Chunk 301
---
 common stock will be subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future. Preferred stock As of June 30, 2025, there were 29,084,235 shares of our redeemable convertible preferred stock outstanding. Immediately prior to the completion of this offering, each outstanding share of redeemable convertible preferred stock will convert into one share of our common stock pursuant to the Preferred Stock Conversion. 223

Upon the filing and effectiveness of our Post-IPO Certificate of
Incorporation, our Board of Directors may, without further action by our stockholders, fix the rights, preferences, privileges, and restrictions of up to an aggregate of 50,000,000 shares of preferred stock in one or more series and authorize their
issuance. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the
designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our common stock, and the likelihood that such holders will
receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring, or preventing a change of control or other corporate action. Upon the completion of this offering, no
shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock.

Stock options

As of June 30, 2025, options to purchase an aggregate of 8,930,919 shares of common stock were outstanding at a weighted-average exercise price of approximately
$10.59 per share. For additional information regarding the terms of our stock options outstanding under our 2018 Plan, see the section titled “Executive compensation—Equity plans.”

Warrants

As of June 30, 2025, we had outstanding warrants to purchase
(i) an aggregate of up to 80,357 shares of our common stock with an exercise price of $2.80 per share (the 2021 Common Warrant), (ii) an aggregate of up to 41,209 shares of our common stock with an exercise price of $10.92 per share (the 2022
Common Warrant and together with the 2021 Common Warrant,